CR20250035A - Inhibidores de acc novedosos - Google Patents
Inhibidores de acc novedososInfo
- Publication number
- CR20250035A CR20250035A CR20250035A CR20250035A CR20250035A CR 20250035 A CR20250035 A CR 20250035A CR 20250035 A CR20250035 A CR 20250035A CR 20250035 A CR20250035 A CR 20250035A CR 20250035 A CR20250035 A CR 20250035A
- Authority
- CR
- Costa Rica
- Prior art keywords
- sub
- alkyl
- pharmaceutically acceptable
- group
- conr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Abstract
Un compuesto que tiene las estructuras: (I) o una sal farmacéuticamente aceptable de este, o un solvato farmacéuticamente aceptable de dicho compuesto o sal farmacéuticamente aceptable, donde; R seleccionado del grupo que consiste en H, alquilo C1-C6, alcoxi C1-C6 y -(CH2)m-W, donde W es cicloalquilo C3-C8, bicicloalquilo, bicicloalquilo puenteado, fenilo, heteroarilo de 5 o 6 miembros o heterociclo que contiene uno, dos o tres heteroátomos seleccionados del grupo que consiste en átomos de N, S y O; donde cada uno de dichos alquilo, cicloalquilo, alcoxi, heterociclo, fenilo, naftilo o heteroarilo puede estar sin sustituir o sustituido por fenilo, halo, ciano, deuterio, hidroxi, alquilo C1-C6, alcoxi C1-C6, -SO2-R', -CONR'R", NR'COR", -NR'CONR'R", -NR'CO2R", -(CH2)n-SO2-R', -NHSO2-R', -NR "SO2-R', -SO2NR'R", NR'R" o SR' donde R' y R'' son independientemente H, alquilo C1-C6 o cicloalquilo C3-C8; R<sub>1</sub> se selecciona del grupo que consiste de fenilos, naftilos, heteroarilos de 5 o 6 miembros, o heterociclos que contienen uno, dos, tres o cuatro heteroátomos seleccionados del grupo que consiste de átomos N, S y O; y bicicloarilo de 9 o 10 miembros, heteroarilo o heterociclo que contiene uno, dos o tres heteroátomos seleccionados del grupo que consiste de átomos N, S y O; en donde cada uno de estos fenilos, naftilos, arilos, heterocíclicos, o heteroarilos pueden ser no sustituidos o sustituidos por halo, ciano, deuterio, hidroxi, C<sub>1</sub>-C<sub>6 </sub>alquilo, C<sub>1</sub>-C<sub>6 </sub>alcoxi, fenilo, -SO<sub>2</sub>-R’, -CONR’R”, NR’COR”, -NR’CONR’R”, -NR’CO<sub>2</sub>R”, -(CH<sub>2</sub>)<em><sub>n</sub></em>-SO<sub>2</sub>-R’, -NHSO<sub>2</sub>-R’, -NR”SO<sub>2</sub>-R’, -SO<sub>2</sub>NR’R”, NR’R”, -P(O)R’R”, o SR’ donde R’ y R’’ son H, C<sub>1</sub>-C<sub>6</sub> alquilo o C<sub>3</sub>-C<sub>8 </sub>cicloalquilo independientemente; y, <em>m </em>y <em>n </em>son independientemente 0, 1, 2 o 3. La invención también se refiere a sales farmacéuticamente aceptables de estos compuestos y a solvatos farmacéuticamente aceptables de los mismos; a composiciones que contienen dichos compuestos; y a los usos de dichos compuestos en el tratamiento de diversas enfermedades, particularmente el acné.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263393712P | 2022-07-29 | 2022-07-29 | |
| PCT/IB2023/057576 WO2024023727A1 (en) | 2022-07-29 | 2023-07-26 | Novel acc inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20250035A true CR20250035A (es) | 2025-03-18 |
Family
ID=87571535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20250035A CR20250035A (es) | 2022-07-29 | 2023-07-26 | Inhibidores de acc novedosos |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20240109915A1 (es) |
| EP (1) | EP4562017A1 (es) |
| JP (1) | JP7734874B2 (es) |
| KR (1) | KR20250037569A (es) |
| CN (1) | CN120019059A (es) |
| AR (1) | AR130069A1 (es) |
| AU (1) | AU2023316863A1 (es) |
| CA (1) | CA3263179A1 (es) |
| CL (1) | CL2025000240A1 (es) |
| CO (1) | CO2025000972A2 (es) |
| CR (1) | CR20250035A (es) |
| DO (1) | DOP2025000009A (es) |
| IL (1) | IL318404A (es) |
| MA (1) | MA71611A (es) |
| MX (1) | MX2025001176A (es) |
| PY (1) | PY2359799A (es) |
| TW (1) | TWI860797B (es) |
| WO (1) | WO2024023727A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025133948A1 (en) * | 2023-12-21 | 2025-06-26 | Pfizer Inc. | Acetyl coa-carboxylase (acc) inhibitors |
| CN119876334B (zh) * | 2025-03-21 | 2025-06-24 | 北京索莱宝科技有限公司 | 乙酰辅酶a羧化酶的酶活测定方法、试剂盒与应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| PE20081559A1 (es) * | 2007-01-12 | 2008-11-20 | Merck & Co Inc | DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA |
| JPWO2008102749A1 (ja) * | 2007-02-20 | 2010-05-27 | 武田薬品工業株式会社 | 複素環化合物 |
| JP2010520293A (ja) | 2007-03-07 | 2010-06-10 | アラントス・フアーマシユーテイカルズ・ホールデイング・インコーポレイテツド | 複素環式部分を含有するメタロプロテアーゼ阻害剤 |
| JP5435592B2 (ja) | 2008-05-28 | 2014-03-05 | ファイザー・インク | ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤 |
| EP2947082A1 (en) * | 2009-11-10 | 2015-11-25 | Pfizer Inc | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS |
| ES2546465T3 (es) * | 2010-10-29 | 2015-09-23 | Pfizer Inc | Inhibidores de N1/N2-lactama acetil-CoA carboxilasa |
| PT2861604T (pt) | 2012-06-08 | 2017-05-05 | Gilead Sciences Inc | Inibidores macrocíclicos de vírus flaviridae |
| US20160220557A1 (en) * | 2013-09-12 | 2016-08-04 | Pfizer Inc. | Use of acetyl-coa carboxylase inhibitors for treating acne vulgaris |
| US20220041616A1 (en) | 2018-11-20 | 2022-02-10 | The National Institutes of Pharmaceutical R&D Co., Ltd. | Spiro compound and medical uses thereof |
| WO2021026672A1 (en) | 2019-08-09 | 2021-02-18 | Novartis Ag | Heterocyclic wdr5 inhibitors as anti-cancer compounds |
-
2023
- 2023-07-26 MA MA71611A patent/MA71611A/fr unknown
- 2023-07-26 US US18/359,709 patent/US20240109915A1/en active Pending
- 2023-07-26 KR KR1020257005913A patent/KR20250037569A/ko active Pending
- 2023-07-26 JP JP2025504407A patent/JP7734874B2/ja active Active
- 2023-07-26 MX MX2025001176A patent/MX2025001176A/es unknown
- 2023-07-26 WO PCT/IB2023/057576 patent/WO2024023727A1/en not_active Ceased
- 2023-07-26 AU AU2023316863A patent/AU2023316863A1/en active Pending
- 2023-07-26 CA CA3263179A patent/CA3263179A1/en active Pending
- 2023-07-26 CR CR20250035A patent/CR20250035A/es unknown
- 2023-07-26 IL IL318404A patent/IL318404A/en unknown
- 2023-07-26 EP EP23754416.8A patent/EP4562017A1/en active Pending
- 2023-07-26 CN CN202380069234.9A patent/CN120019059A/zh active Pending
- 2023-07-28 TW TW112128307A patent/TWI860797B/zh active
- 2023-07-28 AR ARP230102002A patent/AR130069A1/es unknown
- 2023-07-28 PY PY202302359799A patent/PY2359799A/es unknown
-
2025
- 2025-01-27 CL CL2025000240A patent/CL2025000240A1/es unknown
- 2025-01-28 DO DO2025000009A patent/DOP2025000009A/es unknown
- 2025-01-29 CO CONC2025/0000972A patent/CO2025000972A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7734874B2 (ja) | 2025-09-05 |
| MA71611A (fr) | 2025-05-30 |
| CA3263179A1 (en) | 2024-02-01 |
| US20240109915A1 (en) | 2024-04-04 |
| CO2025000972A2 (es) | 2025-02-13 |
| KR20250037569A (ko) | 2025-03-17 |
| TW202415668A (zh) | 2024-04-16 |
| PY2359799A (es) | 2024-02-02 |
| EP4562017A1 (en) | 2025-06-04 |
| CL2025000240A1 (es) | 2025-05-09 |
| DOP2025000009A (es) | 2025-04-08 |
| MX2025001176A (es) | 2025-03-07 |
| AU2023316863A1 (en) | 2025-02-13 |
| AR130069A1 (es) | 2024-10-30 |
| TWI860797B (zh) | 2024-11-01 |
| CN120019059A (zh) | 2025-05-16 |
| JP2025524984A (ja) | 2025-08-01 |
| WO2024023727A1 (en) | 2024-02-01 |
| IL318404A (en) | 2025-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2025000972A2 (es) | Inhibidores de acc novedosos | |
| AR121914A1 (es) | Compuestos útiles para inhibir la quinasa ret | |
| AR117424A1 (es) | Inhibidores de los receptores erbb | |
| MX2016014878A (es) | Pirazolopiridinas y pirazolopirimidinas. | |
| AR126693A1 (es) | Compuestos de pirazolopiridinona | |
| PE20241476A1 (es) | Inhibidores de la ras | |
| PE20242099A1 (es) | Compuestos de piridotriazina sustituidos y usos de estos | |
| AR057772A1 (es) | Derivados de imidazol como inhibidores de sintasa de aldosterona y aromatasa. composiciones farmaceuticas | |
| AR117616A1 (es) | Compuestos anti-vih | |
| AR118435A1 (es) | Compuestos de aza-benzotiofeno y aza-benzofurano como antihelmínticos | |
| AR061106A1 (es) | Pteridinas sustituidas y composiciones farmaceuticas que las contienen. | |
| PE20240775A1 (es) | Compuestos antivirales | |
| ES2171189T3 (es) | Derivados de fenilo tri-sustituidos utiles como inhibidores de pde iv. | |
| AR082886A1 (es) | Compuestos y composiciones farmaceuticas que los contienen | |
| AR123648A1 (es) | Compuestos de carbamoilpiridona tricíclicos puenteados y sus usos | |
| CO5550398A2 (es) | 7-aminotriazolpirimidinas, proceso e intermedios para su preparacion, composiciones que las comprenden y su uso para controlar hongos dañinos | |
| AR116022A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
| AR042067A1 (es) | Derivados de anilinopirazol utiles en el tratamiento de la diabetes | |
| PE20250118A1 (es) | Inhibidores de mutacion de her2 | |
| AR128440A1 (es) | Inhibidores de cinasas raf | |
| PE20242216A1 (es) | Compuestos de heteroaril-urea novedosos como inhibidores de kv7.2 | |
| AR043537A1 (es) | Derivados azabiciclicos de piridiloximetilo y bencisoxazol | |
| CO5660261A2 (es) | Derivados de bencimidazol, composiciones que los contienen, preparacion de estos y usos de estos | |
| AR049097A1 (es) | Derivados de pirimidina para tratar el crecimiento celular anomalo | |
| AR120324A1 (es) | Inhibidores de o-glucoproteína-2-acetamido-2-deoxi-3-d-glucopiranosidasa espirocíclica |